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Type 1 diabetes (T1D) is caused by autoreactive T cells
that recognize pancreatic islet antigens and destroy insulin-
producing b-cells. This attack results from a breakdown in
tolerance for self-antigens, which is controlled by ectopic
antigen expression in the thymus and pancreatic lymph
nodes (PLNs). The autoantigens known to be involved in-
clude a set of islet proteins, such as insulin, GAD65, IA-2,
and ZnT8. In an attempt to identify additional antigenic
proteins, we performed an expression-based genome-
wide association study using microarray data from 118
arrays of the thymus and PLNs of T1D mice. We ranked
all 16,089 protein-coding genes by the likelihood of finding
repeated differential expression and the degree of tissue
specificity for pancreatic islets. The top autoantigen can-
didate was vitamin D–binding protein (VDBP). T-cell pro-
liferation assays showed stronger T-cell reactivity to VDBP
compared with control stimulations. Higher levels and fre-
quencies of serum anti-VDBP autoantibodies (VDBP-Abs)
were identified in patients with T1D (n = 331) than in
healthy control subjects (n = 77). Serum vitamin D levels
were negatively correlated with VDBP-Ab levels in pa-
tients in whom T1D developed during the winter. Immu-
nohistochemical localization revealed that VDBP was
specifically expressed in a-cells of pancreatic islets.
We propose that VDBP could be an autoantigen in T1D.
Type 1 diabetes (T1D) is a multifactorial polygenic disease
caused by self-reactive T-cells that recognize pancreatic
islet antigens and destroy their own pancreatic islet insulin-
producing b-cells. This process leads to severe hypergly-
cemia, lifelong dependence on exogenous insulin, and
potentially severe chronic complications that increase the
risk of premature mortality (1,2). Autoimmune attack may
result from a failure in central and/or peripheral tolerance
that is controlled by expression of peripheral tissue an-
tigen (PTA) in the thymus and pancreatic lymph nodes
(PLNs). Central tolerance is enforced by medullary thy-
mic epithelial cells that ectopically express a range of PTAs
under the transcriptional control of Aire, an autoimmune
regulator (3).
We and others have shown that peripheral tolerance is
mediated by the ectopic expression of PTAs in stromal
cells of peripheral lymph nodes, including the PLN. PTA
expression is controlled by a transcription regulator called
deformed epidermal autoregulatory factor 1 (Deaf1). Dur-
ing the progression of T1D, inflammation and hypergly-
cemia lead to alternative splicing of Deaf1 and reduce PTA
expression in the PLN (4–6). These PTAs include a set of
islet-specific autoantigens critical for disease development,
such as insulin (INS), GAD 65 kDa (GAD65), islet antigen-2
(IA-2), zinc transporter 8 (ZnT8), and chromogranin A
(CHGA) (3,5,7–9).
Studies of T1D genetics have long supported a model
in which the major risk factor for T1D resides in the HLA
region. Candidate gene association studies and genome-wide
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association studies (GWAS) have revealed additional loci,
including insulin (INS); cytotoxic T-lymphocyte antigen 4
(CTLA4); protein tyrosine phosphatase, nonreceptor type
22 (PTPN22); interleukin 2 receptor a (IL2RA); and inter-
leukin 7 receptor (IL7R) (10). These genes have substan-
tially expanded our knowledge of the genetic architecture
and functional aspects of adaptive immunity in T1D. How-
ever, they do not fully explain the molecular mechanisms
underlying pathogenesis and have provided little insight
into other possible autoantigens.
We have described a new meta-analytic methodology,
gene expression–based GWAS (eGWAS), that is a compu-
tational approach for calculating the likelihood of repeated
differential expression for every gene across a large number
of case-controlled gene-expression microarray experiments
(11). Genes that are most repeatedly implicated across a
large set of experimental representations of polygenic
diseases serve as data-driven causal disease genes and are
candidates for further analysis. We used eGWAS to study
type 2 diabetes, integrating 130 independent, publicly avail-
able microarray experiments totaling 1,175 samples (11).
We identified the immune receptor CD44 as the top func-
tional candidate and by using mouse models and human
samples, verified that it plays a novel causative role in the
development of type 2 diabetes (11–13). These findings
were later reproduced and verified in the same mouse strain
by other researchers (14,15).
In T1D, autoimmune reactivity spreads from one protein
to another during the induction and progression of disease;
this process is called epitope spreading (16,17). Immune
recognition of islet-specific autoantigens is one of the prin-
cipal pathogenic factors. Of note, some of these antigens
are present not only in b-cells but also in other endocrine
cells in the pancreas, such as a-cells adjacent to b-cells (7).
Autoantibodies against islet cell antigens have served as
diagnostic biomarkers for islet autoimmunity in patients
with diabetes and prediabetes. They are also useful as pre-
dictive markers for subjects with prediabetes. Four anti-
bodies that react to INS, GAD65, IA-2, or ZnT8 have been
identified and tested as predictive markers of T1D in at-risk
children (18). The chance of progression to T1D within 10
years after islet autoantibody seroconversion with a single-
islet autoantibody was found to be 14.5%. Subjects with
two or more autoantibodies had a 69.7% chance of T1D
developing within 10 years (19).
Identifying additional autoantigens could expand our
understanding of epitope spreading and improve the risk
assessment and prediction of disease progression in T1D.
We have attempted to identify potential candidates by
applying our eGWAS methodology to data obtained from
the thymus and PLN of NOD mice. The NOD mouse has
been established as a genetically susceptible animal model
of autoimmune diabetes in which progression of the dis-
ease closely resembles that of T1D in humans (20). We hy-
pothesized that genes that are most repeatedly dysregulated
across a large set of experimental representations of T1D
in the thymus and PLN may serve as data-driven T1D
autoantigens and are candidates for validation. This ap-
proach is aided by the increasing amounts of publicly
available raw microarray experimental results. We meta-
analyzed 17 independent genome-wide gene-expression
experiments, totaling 118 case and control samples from
the thymus and PLN. We identified a top candidate and
performed confirmatory studies using samples obtained
from the NOD mouse model of T1D and human subjects
(Supplementary Fig. 1).
RESEARCH DESIGN AND METHODS
eGWAS
An eGWAS was performed as previously described (11).
All T1D-related genome-wide microarray experiments
used for this study were collected from the National Cen-
ter for Biotechnology Information Gene Expression Om-
nibus (www.ncbi.nlm.nih.gov/geo). Studies were found using
the following key words: (“type 1 diabetes” OR “T1D”) AND
(“thymus”OR “pancreatic lymph nodes”OR “PLN”). We iden-
tified 118 array samples (58 subjects with T1D and 60 con-
trol subjects) in 17 independent data sets (Supplementary
Table 1). To estimate differences between samples from sub-
jects with diabetes and control subjects, raw postquantitation
microarray data were reanalyzed using Significance Analysis
of Microarrays software (21). For each gene in every micro-
array experiment, we calculated a D score (di), which denotes
the standardized change in gene expression (Eq. 1):
di ¼ xi2t1d2 xi2control
Si þ S0 (Eq. 1)
Here, is the mean expression level of gene i in the
T1D group, is the mean expression level of gene i
in the control group, Si is the SD for the numerator calcu-
lation, and S0 is a small positive constant. We considered
genes to be significantly dysregulated with either an abso-
lute value of the di $2 or a fold change $2 between control
and case samples. We then converted all probe identifiers
across the various mouse microarray platforms to the latest
human Entrez Gene identifiers by using our Array Informa-
tion Library Universal Navigator system (22). Gene expres-
sion profiles were assigned in our eGWAS database according
to the standardized human Entrez Gene identifier. We
counted the observed number of microarray experiments in
which each gene was significantly dysregulated. We then
calculated P values from the number of positive/negative
experiments for each gene and the sum of the number of
positive/negative experiments for all other genes by using a
2 3 2 x2 analysis. A tissue specificity index (TSI) for pancre-
atic islets (= log10 [signal intensity of pancreatic islets/mean
signal intensity of all other tissues]) was calculated for every
gene by using multitissue transcriptome data downloaded
from BioGPS (http://biogps.org/dataset).
Mice
Female NOD/ShiJcl (NOD) mice were purchased from
CLEA Japan, Inc. (Tokyo, Japan). They were housed in a
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barrier facility under specific pathogen-free conditions. The
Animal Care and Use Committee of Kitasato University
(Tokyo, Japan) approved all animal experiments.
T-Cell Proliferation Assay
Antigen-induced blastogenesis was measured in spleen cells
from 4-, 8-, or 12-week-old female NOD mice (n = 5).
Recombinant vitamin D–binding protein (VDBP) produced
in yeast (GenScript, Piscataway, NJ), recombinant GAD65
produced in yeast (RSR, Cardiff, U.K.), or regular insulin
(Novo Nordisk) was used for this assay. Splenocytes (5 3
106 cells/mL) were plated into a 96-well microtiter plate with
10 mg/mL individual islet antigens and cultured at 37°C,
5% CO2, and 95% humidity for 48 h. BrdU was added to
the cell suspension to a concentration of 10 mmol/L, and
incubation was continued for an additional 8 h. Superna-
tants were removed, and a peroxidase-labeled anti-BrdU
reagent was added. After 60 min, tetramethylbenzidine
substrate was added for color development. Results were
read on an ELISA reader. The stimulation index (SI) was
calculated by dividing antigen-induced proliferation by no-
antigen control. Interferon-g (IFN-g) release was measured
by ELISA in supernatants (R&D Systems, Minneapolis, MN).
Human Subjects
We analyzed serum samples from 331 randomly selected
patients (mean age 6 SD 12.2 6 6.8 years, male/female
sex 163/168) who had been given a diagnosis of T1D in
the previous 6 months at the Barbara Davis Center for
Childhood Diabetes (Aurora, CO). All patients had at least
one islet autoantibody present (INS, GAD65, IA-2, and
ZnT8). Of the 331 patients, 34 were positive for transglu-
taminase autoantibodies (related to celiac disease) and 4
were positive for 21-hydroxylase autoantibodies (Addison
disease). Patients taking vitamin D medication were not
included in this study. In addition, 77 healthy control sub-
jects negative for all islet autoantibodies were also included
(mean age 16.96 6.0 years, male/female sex 30/47). Signed
informed consent was obtained from all subjects, and the
study was approved by the institutional review board of the
University of Colorado (Aurora, CO).
VDBP Autoantibody-Autoantigen Complex Detection
Serum diluted five times (20 mL) was incubated with
20 mL of biotinylated goat anti-human IgG monoclonal an-
tibody in PBS for 1 h at room temperature followed by
plate capture with a streptavidin-coated plate (Meso Scale
Discovery, Gaithersburg, MD). The plate was incubated
for 1 h at room temperature and then washed three times
with PBS containing 0.1% Tween-20. Finally, 30 mL mouse
anti-human VDBP monoclonal antibody (ab23484 [species
reactivity: human]; Abcam, Cambridge, MA) was added to
each well and incubated for 2 h at room temperature. The
plate was then washed three times with PBS containing
0.1% Tween-20 and counted on a SECTOR Imager 2400
(Meso Scale Discovery). An assay cutoff index of 0.020 was
based on the 100th percentile and mean 6 3 SD of the
sample set from 77 healthy control subjects after removing
11 outliers. The interassay coefficient of variation was 9.8%
(n = 6).
25-Hydroxyvitamin D Assay
Serum concentrations of 25-hydroxyvitamin D (25OHD)
were measured in a Clinical Laboratory Improvement
Amendments–certified clinical laboratory of Children’s Hos-
pital Colorado by using a commercial kit with an automated
chemiluminescence immunoassay (Immunodiagnostic Sys-
tems, Gaithersburg, MD). All samples were coded, and the
assay was performed in a blinded fashion.
Immunohistochemistry
Immunohistochemical staining of frozen sections (humans)
or paraffin sections (mice) was performed as previously
described (11,23). Human pancreas samples from islet
autoantibody–positive donors were obtained through the
Network for Pancreatic Organ Donors with Diabetes (nPOD)
of JDRF. Mouse pancreatic tissues were harvested from
8-week-old prediabetic NOD mice. Primary and secondary
antibodies used for multiple immunofluorescence labeling
are listed in Supplementary Table 2.
Statistics
For verification studies in mice and human subjects, com-
parisons between two groups were performed using a
two-tailed Welch t test, a Wilcoxon rank sum test, or a
Fisher exact test. P , 0.05 was considered significant. All
experimental data are represented as mean 6 SE unless
otherwise noted.
RESULTS
eGWAS Identifies VDBP as a T1D Autoantigen
Candidate
We carried out an eGWAS for T1D by using 17 independent
microarray experiments, totaling 118 case and control
samples from the thymus and PLN (RESEARCH DESIGN AND
METHODS). Sample data were collected from a public
repository (Supplementary Table 1). For all 16,089
protein-coding genes, we calculated the likelihood that
repeated differential expression for every gene was due
to chance (Supplementary Fig. 2). We filtered the list for
pancreatic islet–specific genes by using a public human
multitissue transcriptome database (BioGPS), yielding
246 genes (24). We then ranked these genes by the TSI for
human pancreatic islets and combined this value with
eGWAS data (Fig. 1 and RESEARCH DESIGN AND METHODS). The
set of genes with high TSI values that were also at the top
of the eGWAS list includes several known T1D autoanti-
gens, such as INS, GAD65, and CHGA. VDBP was our top
autoantigen candidate (eGWAS P = 2.8 3 10211, TSI =
1.75) (Fig. 1). This protein was most frequently down-
regulated in the thymus and PLN across multiple micro-
array experiments in NOD mice and highly expressed in
human pancreatic islet tissues (Fig. 1 and Supplementary
Fig. 3).
VDBP, also known as group-specific component (GC), is
located on chromosome 4q13 and codes for a glycosylated
a-globulin found in blood plasma. It binds to vitamin D
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and its plasma metabolites and transports them to target
tissues (25).
T-Cell Reactivity Against VDBP Is Increased
To examine whether VDBP exhibits antigenicity dur-
ing T1D progression in rodent models, we measured
antigen-induced blastogenesis for VDBP and known islet
autoantigens (INS and GAD65) in spleen cells from 4-, 8-, or
12-week-old female NOD mice (five per group). At 8 weeks
of age, we found striking T-cell reactivity against VDBP
(SI 3.38 6 0.41) that was stronger than INS (SI 1.40 6
0.14), GAD65 (SI 1.36 6 0.13), and control samples (Fig.
2A). At 4 and 12 weeks of age, there also was stronger
reactivity against VDBP compared with control samples.
Reactivity against INS and GAD65 was higher than in
control samples in all age-groups. In addition, we mea-
sured the release of IFN-g in the culture supernatant of
the T-cell proliferation assay by ELISA. The levels of IFN-g
were higher in the VDBP- and INS-stimulated groups
compared with the control group (Fig. 2B).
VDBP Autoantibodies in Patients With T1D
We designed an assay to identify the autoantibody-
autoantigen (Ab-Ag) complex of VDBP in serum (Supple-
mentary Fig. 4). A standard assay designed to detect VDBP
antibodies failed to detect any signal and showed only
background levels (data not shown). Because excess VDBP
protein in circulating blood (26) could saturate VDBP au-
toantibodies (VDBP-Abs), we designed a new assay to cap-
ture VDBP Ab-Ag complexes. This assay found high levels
of VDBP Ab-Ag complexes in the blood of patients with
T1D. VDBP Ab-Ag complex levels in 331 patients with
newly diagnosed T1D were higher than levels in 77 healthy
control subjects (Wilcoxon rank sum test P , 0.0001) (Fig.
3). With the assay cutoff set at an index of 0.020, 27.5%
(91 of 331) of subjects were positive in the T1D group
versus only 14.3% (11 of 77) in the control group (Fisher
exact test P = 0.004). Furthermore, eight patients with
T1D had dramatically high signals (.0.220), which was not
seen in control subjects. We found no correlation of
VDBP-Ab positivity with autoantibody positivity in each
of the six autoantibodies (INS, GAD65, IA-2, ZnT8,
transglutaminase, and 21-hydroxylase).
VDBP-Ab Levels Are Inversely Correlated With Serum
Vitamin D Levels in Patients With T1D During Winter
Vitamin D has a wide spectrum of activity, including
calcium and bone homeostasis, cardiovascular function,
and skin and muscle cell proliferation. It is derived from
a limited number of foods, and its primary source comes
from skin conversion of 7-dehydrocholesterol induced by
exposure to solar ultraviolet B radiation. Low exposure to
sunlight during winter can lead to vitamin D insufficiency.
It has been reported that in northern Canadians, serum
25OHD concentrations are lower in winter and higher in
summer, and in contrast, transporter VDBP concentrations
are higher in winter and lower in summer (27). We there-
fore assumed that VDBP-Ab may have different interac-
tions seasonally with vitamin D metabolism. The level of
serum 25OHD is considered a reliable indicator of vitamin
D levels because of its long serum half-life and lack of
hormonal control by hepatic 25-hydroxylase (28). To assess
the seasonal association of VDBP-Ab with vitamin D status,
we measured serum 25OHD levels in patients with T1D
who were positive for VDBP-Ab (index .0.020) and per-
formed a correlational analysis between serum concentra-
tions of 25OHD and levels of VDBP-Ab. The concentration
of 25OHD was inversely correlated with levels of VDBP-Ab in
blood samples collected during the wintertime (November–
April) (n = 29, r2 = 0.14, P = 0.049). No correlation was
observed during the summertime (n = 34, r2 = 0.0021, P =
0.80) (Fig. 4).
VDBP Is Specifically Expressed in a-Cells of
Pancreatic Islets
VDBP is synthesized and secreted by the liver. It is also
expressed by pancreatic islet cells (29,30). Thus, we in-
vestigated its localization in pancreatic islets. Immuno-
histochemistry was performed to detect VDBP, a-cells
(glucagon), and b-cells (insulin) in pancreatic tissue sec-
tions of human subjects with islet autoantibody positivity
(Fig. 5 and Supplementary Figs. 5 and 6) and prediabetic
NOD mice (Supplementary Fig. 7). VDBP was highly and
specifically expressed in a-cells of pancreatic islets in both
species.
DISCUSSION
T1D is a polygenic autoimmune disease in which effector
T cells mistakenly attack and destroy insulin-producing
b-cells in pancreatic islets (cellular immune responses).
The immune system is believed to lose tolerance to .10
Figure 1—Identification of possible autoantigenic proteins in T1D.
Pancreatic islet specificity is plotted against the likelihood of fre-
quent differential expression in thymus and PLNs.
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islet self-antigens, including INS, GAD65, IA-2, ZnT8, and
CHGA (7). T-cell reactivity to islet antigens is followed by
activation of additional T cells with various islet antigen
specificities (antigen/epitope spreading) (16,17). Additional
autoreactive T cells may contribute to b-cell destruction
(pathogenic activation) or represent nondestructive islet
autoimmunity (bystander activation). The list of target an-
tigens has gradually increased since the 1970s, and it is
conceivable that additional islet autoantigens will be dis-
covered (7). Many of these antigens are preferentially
expressed not only in b-cells but also in multiple non–b-
cells and other tissues. For instance, GAD65 and IA-2 are
neuroenzymes expressed in b- and non–b-cells of islets
and in the CNS, neurons, testis, and ovary; CHGA is
expressed in neurons and non–b-endocrine cells (a-cells)
(7,31,32). Although why loss of tolerance to certain pro-
teins expressed in b- and non–b-cells and other tissues is
associated only with b-cell–specific pathology and disease is
still a mystery, these proteins could confer autoantigenicity
during the early to midstages of b-cell destruction and
may be involved in the progression of disease, with inter-
molecular antigen recognition occurring as a consequence
of this autoantigenicity. In T1D, immune tolerance to self-
proteins is broken, and cohorts of autoreactive T cells are
recruited around pancreatic islets. This process is intri-
cately involved in T1D pathogenesis, and any information
regarding additional self-antigens is crucial to understanding
the mechanism of antigen spreading in T1D. This informa-
tion could be useful for developing therapies and predictive/
diagnostic biomarkers.
A number of islet autoantigens have been identified
based on the recognition of islet cell proteins (a-, b-, and
d-cells) by human serum autoantibodies (33–37). Other
approaches, including T-cell reactivity, have also led to the
discovery of islet autoantigens (9,38–40). The breakdown
of immune tolerance in T1D may result from the loss of
ectopic PTA expression in thymic and/or peripheral lym-
phoid tissues (i.e., thymus, PLN). We have identified ad-
ditional islet autoantigens by using an in silico approach,
eGWAS. We calculated the likelihood of finding repeated
differential expression of a gene in disease-related tissues
by using a large number of case-control genome-wide
gene-expression arrays. We performed an eGWAS analysis
on data from .100 publicly available microarrays from
the thymus and PLN of the NOD mouse model of T1D.
We identified VDBP, a transporter of vitamin D in the
circulation, as the top candidate for an islet autoantigen.
Across microarrays, VDBP was most frequently downreg-
ulated in the thymus and PLN of NOD mice and is spe-
cifically and highly expressed in human pancreatic islets
based on multitissue transcriptome database data. We
performed additional experiments to determine whether
Figure 2—Proliferative T-cell responses to VDBP and other islet antigens. A: Antigen-induced blastogenesis was measured in spleen cells
from 4-, 8-, or 12-week-old female NOD mice (five per group). Islet antigens examined were GAD65, insulin, and VDBP. The SI was
calculated by dividing antigen-induced proliferation by no-antigen control (-). B: The release of IFN-g was measured by ELISA in super-
natants. Representative data are from one of two independent experiments for each age. *P < 0.05, **P < 0.01, ***P < 0.001 vs. control (-).
w, weeks.
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VDBP possesses antigenicity in T1D and to examine the
cellular localization of VDBP in pancreatic islets.
T-cell reactivity assays performed using splenocytes
from the same strain of mice as those used in the meta-
analyzed microarray experiments showed a strong cellular
autoimmune response to VDBP, which was comparable
with other known antigens, including INS and GAD65.
For the present analysis, we used prediabetic NOD mice
at stages when nondestructive peri-insulitis occurs and
progresses (4 and 8 weeks of age) and invasive insulitis
develops (12 weeks of age). The data suggest that VDBP
may already possess antigenicity during the early stage
Figure 3—VDBP-Ab assay in humans. The levels of VDBP-Ab (index) in 331 patients with newly diagnosed T1D and 77 healthy control
subjects are shown. The dotted line represents an assay cutoff value of index 0.020. In patients with T1D, assays were positive in 27.5% (91
of 331) compared with 14.3% (11 of 77) in healthy control subjects.
Figure 4—Correlation between serum levels of 25OHD and VDBP-Ab in patients with T1D. Concentration of 25OHD in serum was analyzed
in patients with T1D and positive for VDBP-Ab (index >0.020). Correlation analysis was performed between the concentration of 25OHD
and levels of VDBP-Ab in patients with blood samples collected during the winter or summer season.
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of disease progression in NOD mice and that VDBP could
be part of the early antigen spreading cascade during the
progression of T1D.
We have previously developed and extensively vali-
dated nonradioactive islet autoantibody assays for T1D.
The assays use electrochemiluminescence detection and
have excellent sensitivity and specificity compared with
the current standard radioimmunoassays for this purpose
(18,41–43). In the current study, we developed an electro-
chemiluminescence VDBP-Ab assay by using a format sim-
ilar to that for islet autoantibody measurement but with
some modifications to detect VDBP Ab-Ag complexes in
patient sera. The assay showed that VDBP-Ab was present
in higher levels and at higher frequencies in patients with
newly diagnosed T1D compared with healthy control sub-
jects. This result demonstrates that autoimmunity against
VDBP is present in a substantial number of patients with
T1D and that VDBP could be an autoantigen contributing
to the progression of T1D. On the other hand, autoim-
munity to VDBP could be a newly discovered independent
autoimmune phenomenon in humans that occurs with
higher frequency in subjects with existing autoimmune dis-
eases, like T1D. This possibility would explain why some
healthy control subjects were also positive for VDBP-
Ab. A series of large studies in cohorts of patients with
T1D and cohorts of patients with other autoimmune
diseases is needed to validate VDBP autoimmunity and
to further explore its etiology, clinical pathology, and
relationship with T1D and other autoimmune diseases.
VDBP is the primary carrier of vitamin D in the blood-
stream and plays a role in maintaining total levels of
vitamin D in the body (25). Vitamin D is a key regulator
of bone and calcium homeostasis. It is mainly (.90%)
synthesized in the skin by sunlight (44). 25OHD levels
can vary naturally throughout the seasons in some cli-
mates, with lower levels in winter due to lack of sun
exposure. The number of newly diagnosed cases of T1D
is higher in autumn or winter compared with spring or
summer, and the incidence of T1D is much higher in
northern Europe where winter sun exposure is minimal
compared with southern Europe (45,46). A large number
of studies have linked/associated serum 25OHD levels
or vitamin D metabolism–related genes (e.g., CYP27B1,
CYP2R1, VDR) with T1D risk (29,47–53). These studies
have demonstrated that vitamin D insufficiency may in-
crease the risk of T1D onset or autoimmunity in infancy,
Figure 5—Immunohistochemical localization of VDBP in human pancreatic islets. Immunofluorescent double staining was performed to
detect VDBP and glucagon (in a-cells) or insulin (in b-cells) in human pancreas sections obtained from an islet autoantibody-positive
individual (nPOD ID #6090 [VDBP + insulin] and #6170 [VDBP + glucagon]). Frozen sections were incubated with anti-VDBP and anti-
glucagon or anti-insulin antibodies followed by incubation in secondary antisera conjugated to Alexa Fluor 594 (red) or Alexa Fluor 488
(green). Colocalization is shown in yellow. Scale bar = 25 mm.
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early childhood, and young adulthood. They have also
suggested a direct immunomodulatory role for vitamin
D on the autoimmune response in T1D. In the current
study, we found that serum VDBP-Ab levels were in-
versely correlated with 25OHD levels in patients with
T1D. This result enabled us to speculate that vitamin D
insufficiency could induce the increased VDBP autoimmu-
nity. Although islet autoantibodies (humoral immune re-
sponses) are not believed to be directly pathogenic in
T1D, they are important markers of islet autoimmunity.
Further studies are needed to explore the mechanisms
underlying the appearance of VDBP autoreactivity in this
disease. The potential relationship between vitamin D
status and VDBP autoimmunity may shed light on the
role of vitamin D in the etiology and pathology of T1D
and its seasonal/geographical differences.
Finally, immunohistochemistry localized VDBP in the
pancreas of islet autoantibody–positive humans and NOD
mice. High levels of VDBP expression were confirmed in
the target tissue (pancreatic islets) as previously described
by other researchers (29,30). Double-staining experi-
ments showed that like another known antigen, CHGA,
VDBP is expressed in a-cells rather than in b-cells. In
addition, similar to GAD65 and IA-2, VDBP is synthesized
in nontarget tissue (liver). Future studies are needed to
determine the detailed molecular and cellular mechanisms
that lead to the emergence of VDBP autoimmunity in
T1D. These studies may provide hints about how self-
antigens in non–b-cells and/or other tissues can contrib-
ute to b-cell (INS)–specific autoimmune destruction in
T1D. VDBP autoimmunity possibly occurs only in a sub-
group of patients with T1D or occurs as a result of by-
stander activation during antigen spreading, given that
VDBP-Ab positivity occurs at a lower frequency (27.5%)
than IA-2, GAD, INS, and ZnT8 autoantibodies (55–72%)
in the same study cohort (8).
In conclusion, by using a data-driven candidate gene
approach (eGWAS), we discovered that VDBP is expressed
in pancreatic islet a-cells and acquires autoantigenicity
during the development of T1D. VDBP-Abs were more
frequently detected in patients with T1D than in control
subjects and could be an additional T1D biomarker. This
would aid in the prediction of T1D risk and development.
The data also contribute to ongoing research on the role
of vitamin D in the development of T1D and, possibly, in
other autoimmune diseases.
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